Documentation
Summary
EMDB documentation pages are indexed below. These documents are intended to provide user focused guidance on systems and services that are provided by the EMDB or by our partners through our services, in particular our partners of the wwPDB.
Table of contents
- General
- Deposition (OneDep)
- EMDB Services
- Miscellaneous
Contact us
Getting in touch: if anything he needs clarification, please reach out to us at the EMDB helpdesk. Important: for any matters related to an active deposition, please only reach out to us through the OneDep deposition system in the communication module of your active deposition.
General
EMDB data model
Data models which describe entries in the database are maintained by the EMDB and the wwPDB. Users will find two data models in which metadata information on database entries can be found, XML and CIF. In practise, for supplying metadata directly to a deposition, users and software developers should use CIF.
→ View data model documentation
Policies
EMDB policies are developed to convey policies specific to our systems and services. Where the EMDB is a core member of the wwPDB consortium, our EMDB policies were developed to complement wwPDB policies. Our processes are governed by both policy documents and are under continuous review to harmonise them.
Deposition (OneDep)
General deposition
The EMDB maintains a general deposition guide. This document is complimentary to basic OneDep deposition information here. In cases of uncertainty please contact us.
→ Read general deposition guide
→ Open OneDep general deposition guide
Composite map deposition
Depositors can find a guide with specific guidance on how to approach the submission of composite maps and their constituent consensus and focus refinements. This guide aims to provide a strategy for completing this kind of deposition efficiently whilst aligning the entries with community derived policy on composite maps.
→ Read composite map deposition guide
EMDB Services
Search engine
Search of the EMDB is powered by Solr provided by EBI. This drives the search functionality of the website but also up-to-date entry page cross referencing. The system can be utilized to create queries that return archive wide metadata.
→ Explore search engine documentation
→ Check the list of available search fields
Chart builder
Built on top of EMDB search, specialized queries are made by the EMDB Chart Builder to plot archive wide metadata and derivative analyses in live interactive charts.
→ Learn how to use the Chart Builder
EMICSS
This system uses data provided at the point of deposition to systematically search associated databases for information which may be used to enrich the annotations of entries.
Validation Analysis
The validation pipeline developed by the EMDB for 3DEM data and associated model coordinates generates validation data for entries when they are deposited to the wwPDB via OneDep. These are the validation data that are communicated to manuscript peer reviewers via the wwPDB PDF validation report. Additional validation data are generated upon data release (normally upon manuscript publication) and communicated to the public via EMDB entry pages on the validation tab.
→ View validation analysis documentation
API
The EMDB Application Programming Interfaces (APIs) provide rapid, scalable and automatable access to 3DEM reconstruction metadata and data. The APIs currently are dedicated to serve (1) main archive, added-value (2) quality validation and (3) semantic annotation metadata and data. A python wrapper provides unified access to selected endpoints across all of the APIs.
Miscellaneous
Frequently Asked Questions (FAQ)
Answers to common questions about EMDB data, deposition, services, and policies.
→ Browse frequently asked questions
Selected Publications
- Fonseca, N., et al. (in press). Chart Builder: An Interactive Tool for User Driven Data Visualization in the Electron Microscopy Data Bank. Frontiers
- Pintilie, G., et al. (2025). Q-score as a reliability measure for protein, nucleic acid and small-molecule atomic coordinate models derived from 3DEM maps. Acta Cryst. D. doi.org/10.1107/S2059798325005923
- Duraisamy, A. K., et al. (2025). EMICSS: Added-value annotations for EMDB entries. Bioinformatics Advances. doi.org/10.1093/bioadv/vbaf203
- Kleywegt, G. J., et al. (2024). Community recommendations on cryoEM data archiving and validation. IUCrJ. doi.org/10.1107/S2052252524001246
- The wwPDB consortium., (2024). EMDB - the Electron Microscopy Data Bank. Nucleic Acids Research. doi.org/10.1093/nar/gkad1019
- Patwardhan, A., et al. (2017). Building bridges between cellular and molecular structural biology. eLife. doi.org/10.7554/eLife.25835
- Patwardhan, A., et al. (2014). A 3D cellular context for the macromolecular world. Nature Structural & Molecular biology. doi.org/10.1038/nsmb.2897
- Patwardhan, A., et al. (2012). Data management challenges in three-dimensional EM. Nature Structural & Molecular Biology. doi.org/10.1038/nsmb.2426
Under development
Segmentation data model prototype.
Quick links
Recent Entries
(Show all)
Cryo-EM structure of monomeric bovine heart cytochrome c oxidase in amphipol A8-35
Cryo-EM structure of homotypic CENP-A nucleosome isolated from human cells
Structure of Human Aspartate--tRNA ligase 3-154 with linker and FC : ATYR0101
Cryo-EM structure of heterotypic CENP-A/H3 nucleosome isolated from human cells
A composite map of the mitochondrial ATP synthase monomer from Acanthamoeba castellanii
CryoEM structure of respiratory complex III intermediate from Acanthamoeba castellanii
Mitochondrial MDH and OSCP in the peripheral stalk of ATP synthase in Acanthamoeba castellanii
Membrane region of Acanthamoeba castellanii mitochondrial ATP synthase dimer
Cryo-EM structure of R2Tg bound to template RNA and target DNA in the target-primed reverse transcription initiation state (state 1, Myb domain focused)
Cryo-EM structure of STITCHR (R2Tg and Cas9 nickase) bound to guide RNA, template RNA, and target DNA in the target-primed reverse transcription initiation state
Cryo-EM structure of R2Tg bound to template RNA and target DNA in the target-primed reverse transcription initiation state (state 2)
Cryo-EM structure of R2Tg bound to template RNA and target DNA in the target-primed reverse transcription initiation state (state 3)
A Cryo-EM Map with a Continuous Density of Sld3-CTD Binding on Mcm4-NTD-A and Mcm6-NTD-A
A Local Refined Structure for Sld7 in Complex with Dbf4-bound Mcm6
A Cryo-EM map for Sld3-Sld7 on Cdc45 and DDK-bound MCM Double Hexamer with a Highly Dynamic Sld3N and Sld7N
Cryo-EM structure of R2Tg bound to template RNA and target DNA in the target-primed reverse transcription initiation state (state 1)
Immune complex comprising the HRSV preF trimer (SC-DM) and the monoclonal antibody Lor69 - Obtained by cryo-EM
Plasmodium falciparum 17-PF subpellicular microtubule associated with human hemoglobin (local refined map)
Plasmodium falciparum 17-PF subpellicular microtubule associated with human hemoglobin
Trans-1-azomorphine-3 bound mu opioid receptor Gi complex - Focused receptor map
Trans-2-azomorphine-3 bound mu opioid receptor Gi complex - Focused receptor map
Trans-2-azomorphine-3 bound mu opioid receptor Gi complex - Focused Gi map
cis-azomorphine-3 bound mu opioid receptor Gi complex - Focused Gi map
Cis-azomorphine-3 bound mu opioid receptor Gi complex - Focused receptor map
Trans-1-azomorphine-3 bound mu opioid receptor Gi complex - Focused Gi map
cAMP-bound SthK monomer from symmetry expanded particles - POPA class 1
cAMP-bound SthK monomer from symmetry expanded particles - POPA class 2
cAMP-bound SthK monomer from symmetry expanded particles - POPA class 3
cAMP-bound SthK monomer from symmetry expanded particles - POPA class 4
cAMP-bound SthK monomer from symmetry expanded particles - POPE class 2
cAMP-bound SthK monomer from symmetry expanded particles - POPA class 8
cAMP-bound SthK monomer from symmetry expanded particles - POPA class 6
cAMP-bound SthK monomer from symmetry expanded particles - POPA class 7
cAMP-bound SthK monomer from symmetry expanded particles - POPA class 5
cAMP-bound SthK monomer from symmetry expanded particles - POPE class 1
Cryo-EM structure of the flagellar filament in Vibrio parahaemolyticus VP288
Structure of Class II chitin synthase, Chs1, from Candida albicans (CaChs1), bound to diynyl arylamine (DA, aka RO-09-3143)
Candida albicans Chitin synthase 1 (CaChs1) intermediate state (DA-7), bound to UDP and diynyl arylamine (DA, aka RO-09-3143)
Candida albicans Chitin synthase 1 (CaChs1) intermediate state (DA-4), bound to UDP and diynyl arylamine (DA, aka RO-09-3143)
Structure of Class II chitin synthase, Chs1, from Candida albicans (CaChs1), state 2 (pre-translocation) after 5 min reaction
Structure of Class II chitin synthase, Chs1, from Candida albicans (CaChs1), state 3 (post-translocation) after 5 min reaction
Candida albicans Chitin synthase 1 (CaChs1) bound to UDP-GlcNAc and diynyl arylamine (DA, aka RO-09-3143)
Human CI-M6PR/IGF2R (cation-independent mannose-6-phosphate receptor) cryo-EM structure low pH conformation
Candida albicans Chitin synthase 1 (CaChs1) intermediate state (DA-3), bound to UDP and diynyl arylamine (DA, aka RO-09-3143)
Structure of Class II chitin synthase, Chs1, from Candida albicans (CaChs1) in the apo state
Candida albicans Chitin synthase 1 (CaChs1) intermediate state (DA-5), bound to UDP and diynyl arylamine (DA, aka RO-09-3143)
Candida albicans Chitin synthase 1 (CaChs1) intermediate state (DA-6), bound to UDP and diynyl arylamine (DA, aka RO-09-3143)
Candida albicans Chitin synthase 1 (CaChs1) intermediate state (DA-2), bound to UDP and diynyl arylamine (DA, aka RO-09-3143)
Structure of Class II chitin synthase, Chs1, from Candida albicans (CaChs1), state 1 (post UDP hydrolysis) after 5 min reaction
Drosophila MSLHAT nucleosome complex H4K16ac postcatalytic H3K36me3 reader state overall refinement
MSL HAT nucleosome complex active H4K16Ac state Overall refinement
Drosophila MSL HAT nucleosome complex H4K16ac postcatalytic H3K36me3 reader state focused refinement
Drosophila MSL HAT nucleosome complex H4K16ac post-catalytic state
Cryo-EM map of mouse PADI6-UHRF1-UBE2D2 complex (state 2), featuring a tetrameric assembly of PADI6
Cryo-EM structure of the MRGPRX4-miniGsq complex bound to the inverse agonist cmpd54-4, local
Cryo-EM structure of the MRGPRX4-miniGsq complex bound to the inverse agonist cmpd54-4
Cryo-EM structure of the MRGPRX4-miniGsq complex bound to the agonist dexamethasone phosphate (DEX-P),local
Cryo-EM structure of the MRGPRX4-miniGsq complex in the apo state
Cryo-EM structure of the MRGPRX4-miniGsq complex bound to the agonist dexamethasone phosphate (DEX-P)
Cryo-EM structure of the MRGPRX4-miniGsq complex in the apo state, local
Drosophila MSL HAT nucleosome complex H4K16ac postcatalytic H3K36me3 reader state
Cryo-EM structure of human TMEM45A with a bound 2-Hydroxypalmitate
Nucleosome with an SSB at SHL +5.3 in complex with the WGR domain of human PARP2, Class 1
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 7, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 10
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 9, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 10, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 8, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 10, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 5
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 1
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 9, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 5, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 6
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 1
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 7
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 5
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 7, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 8, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 9
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 3
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 2
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 4
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 2, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 5, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 2, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 4, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 3, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 3, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 4, Focus map
SARS-CoV-2 Omicron JD.1.1 spike trimer (S-6P) in complex with 3 R102-9 Fabs and 3 C092 Fabs, focused refinement of RBD and Fab region
SARS-CoV-2 Omicron JD.1.1 spike trimer (S-6P) in complex with 3 R102-9 Fabs and 3 C092 Fabs (3 RBD up)
Human condensin II bound to ADP-BeF3 in autoinhibited conformation
Cryo-electron tomogram of cryo-FIB milled yeast cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled yeast cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled Tetrahymena thermophila cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled yeast cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled yeast cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled mouse brain biopsy frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled Tetrahymena thermophila cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled yeast cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled mouse brain biopsy frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled Tetrahymena thermophila cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled yeast cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled yeast cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled Tetrahymena thermophila cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled yeast cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled mouse brain biopsy frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled yeast cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled yeast cells frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled yeast cells frozen in HPF Autogrid Planchettes
In-situ structure of the 80S yeast ribosome frozen in HPF Autogrid Planchettes
Cryo-electron tomogram of cryo-FIB milled Tetrahymena thermophila cells frozen in HPF Autogrid Planchettes
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 5, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 5, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 6, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 6, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 2, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 8, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 2, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 4, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 4, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 7, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 7, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 6, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 5, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 6, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 1, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 3, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 4, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 3, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 4, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 6, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 6, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 1, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 5, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 1, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 1, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 1, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 4
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 3
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 5
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 4
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 6
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 7
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 2
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 4
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 8
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 6
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 1
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 8
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 3
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 6
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1 and Olaparib, Class 6
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 3
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 9
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 10
Nucleosome with an SSb at SHL +5.3 in complex with the WGR domain of PARP2, Class 2, consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 8
Structural Insights into HIV-1 Vif-Mediated Ubiquitination and Degradation of APOBEC3H
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 13
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 12
Nucleosome with an SSB at SHL +5.3 in complex with the WGR domain of PARP2, Class 2
Human mitochondrial ClpP in complex with OICR-18704 in a partially-engaged tetradecameric state (intermediate opening)
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 1, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 1, Focused map
Human mitochondrial ClpP in complex with OICR-18704 in a partially-engaged tetradecameric state (minimal opening)
Human mitochondrial ClpP in complex with OICR-18704 in the heptameric state
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 2, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 2, Focused map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 2, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 1, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 1, Focus map
Human mitochondrial ClpP in complex with OICR-18704 in a partially-engaged tetradecameric state (maximal opening)
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 2, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 3, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 3, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 8, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 3, Focused map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 3, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 9, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 9, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 7, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 7, Focus map
Nucleosome with an SSD at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 2
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 7
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 2
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 6, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 4, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 2, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 9
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 7, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 4, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 3, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 3, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 2, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and EB47, Class 6, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1 and Talazoparib, Class 1
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 3
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 2
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Olaparib, Class 5
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 4
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 7
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 5
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 9, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2 and HPF1, Class 9, Focus
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 11, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 11, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 11
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1, and Talazoparib, Class 14, Consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 14, Focus map
Nucleosome with an SSB at SHL +5.3 in complex with the WGR domain of human PARP2, Class 2, focus map
Nucleosome with an SSB at SHL +5.3 in complex with the WGR domain of human PARP2, Class 1, consensus map
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, HPF1 and Olaparib, Class 1
Nucleosome with an SSB at SHL +5.3 in complex with human PARP2, Class 14
Nucleosome with an SSB at SHL +5.3 in complex with the WGR domain of human PARP2, Class 1, focus map
Focused map of the disulfide linked complex of T. ramosa IgA peptidase (IgAse2-4) with human IgA2 Fab' in precatalytic conformation
Cryo-EM structure of CRBN bound to 2-[5-chloro-1-(4-piperidyl)indol-4-yl]-2,5-diazaspiro[3.4]octan-6-one in the open conformation
Disulfide linked complex of T. ramosa IgA peptidase (IgAse2-4) with human IgA2 Fab' in recognition conformation
Disulfide linked complex of T. ramosa IgA peptidase (IgAse2-4) with human IgA2 Fab' in precatalytic conformation
Cryo-EM structure of CRBN bound to 1-[1-(4-piperidyl)indol-4-yl]hexahydropyrimidine-2,4-dione in the open conformation
Raw map of the disulfide linked complex of T. ramosa IgA peptidase (IgAse2-4) with human IgA2 Fab' in recognition conformation
Raw map of the disulfide linked complex of T. ramosa IgA peptidase (IgAse2-4) with human IgA2 Fab' in precatalytic conformation
Cryo-EM structure of CRBN bound to 1-[1-(4-piperidyl)indol-4-yl]hexahydropyrimidine-2,4-dione in the closed conformation
Focused map of the disulfide linked complex of T. ramosa IgA peptidase (IgAse2-4) with human IgA2 Fab' in recognition conformation